Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up.

OBJECTIVE: To assess the improvement in vulvovaginal atrophy (VVA) of postmenopausal women treated with oral ospemifene 60 mg/day under conditions of routine clinical practice after 12 months of follow-up. METHODS: The AYSEX study is a Spanish observational, prospective, and unicentric study in which five gynecologists recruited postmenopausal women with VVA in routine clinical practice treated with oral ospemifene 60 mg/day as an appropriate therapeutic option. Vaginal health, the most bothersome symptoms, sexual health, endometrial safety, bone resorption markers, bone densitometry, mammography, treatment satisfaction, and quality of life were assessed at baseline and after 12 months using appropriate scales. RESULTS: A total of 100 postmenopausal women cytologically and clinically diagnosed with VVA were included in the study. After 3 months of treatment with ospemifene, a significant improvement was observed in all domains of Vaginal Health Index. This improvement was maintained at month 12 and only one patient remained with vaginal atrophy. In addition, a significant improvement was observed in the most bothersome symptoms, sexual function, and quality of life. There was no significant change in endometrial thickness, mammography, and bone health during the 12 months of treatment. CONCLUSIONS: This study in routine clinical practice conditions confirms the results previously reported by randomized controlled trials, including a significant improvement in VVA, sexual function, quality of life, endometrial safety, and satisfaction with the treatment.

Manejo del factor masculino leve a moderado con L-carnitina. Serie de casos / Managing mild to moderate male factor with L-carnitine. Case series

Objetivo: determinar la utilidad de la L-carnitina vía intramuscular de 1 gr como tratamiento para los casos de factor masculino leve a moderado. Materiales y métodos: participaron en el estudio doce sujetos a los cuales se les diagnosticó oligo-asteno-teratozospermia leve a moderada. Se les administró a un grupo L-carnitina a dosis de 1 gr IM cada 4 día por lo menos por 2 meses previo al procedimiento de reproducción asistida al que fueron sometidos junto con sus parejas. Tomamos como control los parámetros espermáticos el día en que se les realizaba el procedimiento. Resultados: en el grupo que utilizó L-carnitina se observó una mejoría significativa al momento de realizar el procedimiento de reproducción asistida en cuanto a los parámetros espermáticos de concentración y en la movilidad, logrando embarazo en un 50 por ciento. Conclusión: el uso de L-carnitina incrementa la concentración y la movilidad de los espermatozoides, mejorando la tasa de embarazo.